力诺药包高管大换血

Group 1 - The core management team of Linuo Pharmaceutical has undergone significant changes, with nearly half of the key management replaced in the last three months [1] - Cao Zhongyong, the former deputy general manager, has resigned but will continue to work in the company, focusing on human resources and overseas business development [1] - Song Lai has taken over as the legal representative and chairman of the company, succeeding Yang Zhongchen, who retired [1] Group 2 - The actual controller of Linuo Pharmaceutical, Gao Yuankun, has joined the board as a non-independent director, indicating a potential shift in strategic direction from the controlling shareholder [1] - The company was listed on the ChiNext board in November 2021, focusing on the research, production, and sales of borosilicate glass, with key products including medicinal glass and heat-resistant glass [1] - In the third quarter report, heat-resistant glass accounted for 57.02% of the main business revenue, while medicinal glass made up 40.74% [1] Group 3 - In 2022, the company's performance declined, with revenue decreasing by 7.52% and net profit dropping by 6.51% [2] - In 2023, the net profit saw a significant decline of 43.49%, following a slight increase of 0.23% in the previous year [2]